Unicycive Therapeutics (UNCY) Cash from Investing Activities (2022 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Cash from Investing Activities came in at -$5.2 million in Q1 2026, down 32118.75% YoY from N/an in Q1 2025, and up 57.29% on a QoQ basis from -$12.1 million in Q4 2025.
Unicycive Therapeutics (UNCY) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 4 years of Cash from Investing Activities data on file, last reported at -$5.2 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 32118.75% year-over-year to -$5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.2 million (down 20917.07% YoY) and the FY2025 annual result came in at -$12.1 million, down 16698.61% from the prior year.
- Cash from Investing Activities improved to -$5.2 million in Q1 2026, from -$12.1 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q1 2022 to a low of -$12.1 million in Q4 2025.
- A 4-year average of -$1.7 million and a median of -$18000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 91.67% in 2025, down 54768.18% in 2025.
- Tracing UNCY's Cash from Investing Activities over 4 years: stood at -$2000.0 in 2022, then plunged by 1000.0% to -$22000.0 in 2024, then plunged by 54768.18% to -$12.1 million in 2025, then surged by 57.29% to -$5.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$5.2 million (Q1 2026), -$12.1 million (Q4 2025), and -$2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23,000.00 |
| Jun 30, 2026 | -23,000.00 |
| Mar 31, 2026 | -5.16 Mn |
| Mar 31, 2026 | -5.16 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -16,000.00 |
| Mar 31, 2025 | -16,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Sep 30, 2024 | -24,000.00 |
| Sep 30, 2024 | -24,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |